Management of Acute Heavy Menstrual Bleeding in Perimenopausal Women with Norethisterone Acetate

Acute Pharmacologic Control

Administer norethisterone acetate 5 mg three times daily (total 15 mg/day) for 10–20 days to achieve rapid hemostasis in women experiencing acute heavy menstrual bleeding. Evidence level not specified. 2
Add an NSA ‑ ibuprofen 400–600 mg three times daily for 5–7 days during the high‑dose progestin phase to further reduce menstrual blood flow. Evidence level not specified. 2

Exclude pregnancy, structural uterine lesions (e.g., polyps, fibroids), thyroid dysfunction, and bleeding disorders prior to starting progestin therapy in women of perimenopausal age. Evidence level not specified. 1

Prior to progestin use, ensure endometrial pathology is ruled out because perimenopausal status increases the risk of underlying endometrial disease. Evidence level not specified. 4
If bleeding is unexplained or raises suspicion for serious pathology, defer hormonal treatment until endometrial sampling or appropriate imaging is completed. Evidence level not specified. 4
Norethisterone acetate is favored over estrogen‑containing regimens in women > 50 years because it avoids estrogen‑related thrombotic risk. Evidence level not specified. 5

Refer women with contraindications to hormonal therapy or who fail oral norethisterone acetate to endometrial ablation or hysterectomy for definitive control of bleeding. Evidence level not specified. 1

Routine follow‑up visits are not required; however, patients should be instructed to return if bleeding persists beyond 3–6 months, if concerning side effects develop, or if bleeding recurs after initial control. Evidence level not specified. 2

Do not rely on norethisterone acetate for contraception during the taper regimen; it is ineffective for pregnancy prevention unless used continuously. Evidence level not specified. 1
Avoid placement of copper intrauterine devices in this setting, as they may exacerbate menstrual bleeding. Evidence level not specified. 1
Do not extend the high‑dose (15 mg/day) norethisterone regimen beyond 20 days without switching to a cyclic schedule, because prolonged continuous high‑dose progestin increases the risk of breakthrough bleeding. Evidence level not specified. 1